Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 12/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14238612 | 1.00 | ADORA1 (0.43) | ADORA1ADORA2AADORA3MEN1KMT2A | |
| SCHEMBL14236364 | 0.86 | ADORA1 (0.48) | ADORA1ADORA2AADORA3MEN1KMT2A | |
| SCHEMBL5635889 | 0.83 | ATF1 (0.39) | ALDH1A1SMN1; SMN2SCN9AKDM4ETBK1 | |
| SCHEMBL5078770 | 0.83 | ATF1 (0.39) | ALDH1A1SMN1; SMN2SCN9AKDM4ETBK1 | |
| SCHEMBL1719342 | 0.77 | LOXL2 (0.39) | ADORA2AALDH1A1L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL1719347 | 0.77 | LOXL2 (0.39) | ADORA2AALDH1A1L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL5074726 | 0.76 | JAK3 (0.40) | ADORA1ADORA2AADORA3TBK1 | |
| SCHEMBL5077837 | 0.76 | JAK3 (0.40) | ADORA1ADORA2AADORA3TBK1 | |
| SCHEMBL14236637 | 0.75 | S1PR2 (0.36) | SCN9AKDM4ETBK1FPR2 | |
| SCHEMBL14853836 | 0.75 | TBK1 (0.37) | ALDH1A1L3MBTL1SMN1; SMN2KDM4ETBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580802-B2 | Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2532667-A1 | Deazapurines useful as inhibitors of janus kinases | Vertex Pharmaceuticals Incorporated (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-1931674-B1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMA (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-1931674-A2 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | Vertex Pharmceuticals Incorporated (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-06 | — | — | US | disclosed |
| WO-2007041130-A2 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | JAK1, JAK3, JAK2 | ADORA1 2488/4885ADORA2A 1467/4885ADORA3 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.